Timothy R.  Franson net worth and biography

Timothy Franson Biography and Net Worth

Director of Cidara Therapeutics
Dr. Franson currently serves as a Principal in the Health and FDA Practice for Faegre Drinker Consulting. From 2014 until 2019, he served as the Chief Medical Officer of YourEncore, an advisory firm focused on global life sciences and consumer health companies. From 2009 until 2014, he was a Principal of FaegreBD Consulting, a clinical and regulatory pharmaceutical development consulting firm, which merged into Faegre Drinker in 2020. In 2008, Dr. Franson founded and served as President of Franson Pharma Advisors LLC, a clinical and regulatory pharmaceutical development consulting firm. Between 1986 and 2008, Dr. Franson held various senior leadership positions at Eli Lilly and Company. At the time of his retirement, he served as Vice President of Global Regulatory Affairs at Lilly Research Laboratories, an Eli Lilly subsidiary. Dr. Franson was integrally involved in global public health initiatives through the U.S. Pharmacopeial Convention (USP), serving as the past President of this organization and on the USP Board of Trustees from 2010 to 2020. He serves on the Board of Directors of Paratek Pharmaceuticals and as the Board Chair for the Critical Path Institute, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics and antibiotic utilization. He holds a B.S. in Pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases and is an Adjunct Professor of Medicine at Indiana University School of Medicine.
 
 
 

How do I contact Timothy R. Franson?

The corporate mailing address for Dr. Franson and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Timothy R. Franson's contact information.

Has Timothy R. Franson been buying or selling shares of Cidara Therapeutics?

Timothy R. Franson has not been actively trading shares of Cidara Therapeutics during the last ninety days. Most recently, on Monday, September 13th, Timothy R. Franson bought 350 shares of Cidara Therapeutics stock. The stock was acquired at an average cost of $42.40 per share, with a total value of $14,840.00. Learn More on Timothy R. Franson's trading history.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $105,680.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,944 shares worth more than $51,223.36. The most recent insider tranaction occured on September, 11th when insider Taylor Sandison sold 924 shares worth more than $10,755.36. Insiders at Cidara Therapeutics own 7.6% of the company. Learn More about insider trades at Cidara Therapeutics.

Information on this page was last updated on 9/11/2024.

Timothy R. Franson Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Buy350$42.40$14,840.00View SEC Filing Icon  
4/20/2015Buy200$320.00$64,000.00View SEC Filing Icon  
See Full Table

Timothy R. Franson Buying and Selling Activity at Cidara Therapeutics

This chart shows Timothy R Franson's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $23.22
Low: $21.20
High: $24.00

50 Day Range

MA: $16.37
Low: $10.17
High: $23.73

2 Week Range

Now: $23.22
Low: $10.00
High: $24.99

Volume

148,362 shs

Average Volume

42,980 shs

Market Capitalization

$163.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13